HSR23-105: Real-World Dosing Patterns in Patients With Anaplastic Lymphoma Kinase Positive (ALK+) Non–Small Cell Lung Cancer (NSCLC) Treated With Brigatinib in the Front-Line (FL) Setting in the United States: A Claims Database Analysis
Journal of The National Comprehensive Cancer Network(2023)
Abstract
"HSR23-105: Real-World Dosing Patterns in Patients With Anaplastic Lymphoma Kinase Positive (ALK+) Non–Small Cell Lung Cancer (NSCLC) Treated With Brigatinib in the Front-Line (FL) Setting in the United States: A Claims Database Analysis" published on 31 Mar 2023 by National Comprehensive Cancer Network.
MoreTranslated text
Key words
anaplastic lymphoma kinase positive,lung cancer,cell lung cancer,non–small cell lung cancer,real-world,front-line
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined